Stay updated with breaking news from Ichnos Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- Differentiated Preclinical Lead Candidate STAR-0310 to be Developed as a Potential Best-in-Class Long-Acting Treatment for Atopic Dermatitis –-- Conference Call and Webcast to be Held on October 12, 2023 at 8:30am ET --BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company f...
Glenmark subsidiary Ichnos will receive up to $320 million in upfront, development, regulatory and sales milestone payments in addition to up to low double-digit royalties
By Ben Glickman Astria Therapeutics entered a global exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential...
By Ben Glickman Shares of Astria Therapeutics rose after the company secured a licensing deal for a potential treatment of atopic dermatitis. The stock was...
/PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, today...